Prognostic Significance of HLA Class I Expressing in Gastric Carcinoma Defined by Monoclonal Anti-Pan HLA Class I Antibody, EMR8-5

Journal of Gastrointestinal Surgery

Volumn 15, Issue 8, 2011, Pages 1336-1343

  Lee, Hae Wan ^a   Min, Soo Kee ^a   Ju, Young Su ^a   Sung, Joohon ^b   Lim, Man Sup ^a   Yang, Dae Hyun ^a   Lee, Bong Hwa ^a  

^a Hallym University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Gastric cancer; Human leukocyte antigen class I; Immunohistochemistry

Indexed keywords

HLA ANTIGEN CLASS 1;

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOMA; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; STOMACH NEOPLASMS;

EID: 79960848138     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1545-3     Document Type: Article

References (29)

1. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999; 5: 178-186.
2. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990; 59: 253-288.
3. Shawar SM, Vyas JM, Rodgers JR, Rich RR. Antigen presentation by major histocompatibility complex class I-B molecules. Annu Rev Immunol 1994; 12: 839-880.
4. Sers C, Kuner R, Falk CS, Lund P, Sueltmann H, Braun M, Buness A, Ruschhaupt M, Conrad J, Mang-Fatehi S, Stelniec I, Krapfenbauer, Poustka A, Schafer R. Down-regulation of HLA class I and NKG2D ligand through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer 2009; 125: 1626-1639.
5. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14: 619-648.
6. Ogino T, Shigyo H, Ishii H, Katayama A, Mivokawa N, Harabuchi Y, Ferrone S. HLA calss I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006; 66: 9281-9289.
7. Kikuchi E, Yamazaki Y, Toigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007; 98: 1424-1430.
8. Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I Antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol 2007; 177: 1269-1272.
9. Homma I, Kitamura H, Torigoe T, Tanaka T, Sato E, Hirohashi Y, Masumori N, Tsukamoto T. Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: Its association with clinical characteristics and survival after cystectomy. Cancer sci 2009; 100: 2331-2334.
10. Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 1374-1380.
11. Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H. Downregulation of HLA class I molecules in the tumor is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 2008; 99: 1462-1467.
12. Speetjens FM, de Bruin EC, Morreau H, Zeestraten EC, Putter H, van Krieken JH, van Buren MM, van Velzen M, Dekker-Ensink NG, van de Velde CJ, Kuppen PJ. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunother 2008; 57: 601-609.
13. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005; 117: 248-255.
14. Menon AG, Morreau H, Tollenaar RA, Alphenaar E, van Puijenbroek M, Putter H, Janssen-van Rhijn CM, van de Velde CJ, Fleuren GJ, Kuppen PJ. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 2002; 82: 1725-1733.
15. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008; 27: 5869-5885.
16. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002; 12: 3-13.
17. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation Int J Cancer 2006; 118: 129-138.
18. Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T. HLA-Class I expression in gastric cancer. J Surg Oncol 2008; 97: 605-608.
19. Ueda Y, Ishikawa K, Shiraishi N, Yokoyama S, Kitano S. Clinical significance of HLA class I heavy chain expression in patients with gastric cancer. J Surg Oncol 2008; 97: 451-455.
20. Shen YQ, Zhang JQ, Miao FQ, Zhang JM, Jiang Q, Chen H, Shan XN, Xie W. Relationship between the down regulation of HLA class I antigen and clinicopathological significance in gastric cancer. World J Gastroenterol 2005; 11: 3628-3631.
21. Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear renal cell carcinoma. J Urology 2007; 177: 1269-1272.
22. Hanak L, Slaby O, Lauerova L, Kren L, Nenutil R, Michalek J. Expression of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy. Med Sci Monit 2009; 15: CR638-643.
23. Hofbauer GF, Burkhart A, Schuler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother 2004; 27: 73-78.
24. Redondo M, Garcia J, Villar E, Rodrigo I, Perea-Milla E, Serrano A, Morell M. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 2003; 34: 1283-1289.
25. Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. 2007; 17: 275-287.
26. Ghodke Y, Joshi K, Chopra A, Patwardhan B. HLA and disease. Eur J Epidemiol 2005; 17: 510-516.
27. Lee HW, Hahm KB, Lee JS, Ju YS, Lee KM, Lee KW. Association of HLA class II alleles with chronic atrophic gastritis and gastric carcinoma. J Dig Dis 2009; 10: 265-271.
28. Yoon JH, Shin S, Park MH, Song EY, Roh EY. HLA-A, -B, -DRB1 allele frequencies and haplotypic association from DNA typing data of 7096 Korean cord blood units. Tissue Antigens 2010; 75: 170-173.
29. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000; 56: 522-529.